FierceBiotech editor to keynote Arizona awards dinner; TG inks pact with Rhizen;

Conversations on Twitter :

 @FierceBiotech: IMS bags planning tech for clinical trials with TTC buyout. News | Follow @FierceBiotech

 @JohnCFierce: Idenix shares eviscerated as clinical hold raises tox fears. Article | Follow @JohnCFierce

 @RyanMFierce: I'm planning a trip to visit my biotech neighbors to the north in Montreal. Looking forward to putting faces to names and so forth. | Follow @RyanMFierce

> FierceBiotech Editor John Carroll is keynoting the annual awards dinner for the Arizona BioIndustry Association on October 23. "We need to stay focused on the road ahead if we are to continue to keep moving forward faster," says AZBio CEO Joan Koerber-Walker. "Having John D. Carroll's global view and industry insights to share with our community will help us do just that." Story

> TG Therapeutics, a low profile biotech which went public through a merger with Manhattan recently, has completed a collaboration deal with Rhizen Pharmaceuticals on a PI3K delta inhibitor. The deal touts $250 million in potential milestones. Release

> Investor's Business Daily profiles Impax Laboratories ($IPXL), which has been developing a possibly "game-changing" Parkinson's drug. Story

Pharma News

 @FiercePharma: Maybe K-V Pharma should have listened to Facebook as the Makena pricing furor grew: More | Follow @FiercePharma

> Guess who's coming to dinner, Howard? More

> Abbott's CEO paycheck bigger than its tax bill, study says. Article

> U.K. docs don't see sales reps, and don't use pharma's websites, either. Story

Medical Device News

 @FierceMedDev: Is Boston Sci still reeling from its $28B purchase of Guidant? More | Follow @FierceMedDev

 @MarkHFierce: Mission accomplished: Sunshine Heart closes public offering of common stock and pulls in $18 million. Item | Follow @MarkHFierce

 @DamianFierce: Regulus has signed on with Biogen Idec to develop microRNA diagnostics for MS. News | Follow @DamianFierce

> Dartmouth developing device-controlling wristwatch. Story

> FDA sticks Class I tag on Covidien recall. News

Vaccines News

> Antigen Discovery receives $2.5M grant for malaria vax. Item

> Heart disease vaccine steps closer. Report

> Feds cut Ebola vax funding. More

> FDA approves 6 flu vaccines. Story

Pharma Manufacturing News

> It is overfilled pain drug in latest Hospira recall. News

> Morphotek turns to manufacturing with new plant. Story

> West-Ward plant problems undermine Hikma earnings. Article

And Finally… Investigators say that a daily dose of chocolate could lower blood pressure, but they still recommend diet and exercise as the best approach. Story

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

The phase 2 trial will generate data to support a filing for approval of COVID-19 vaccine BNT162b2 in China.